(9-450) Analyzing the safety and efficacy of high versus low dose recombinant activated Factor VIIa (NovoSeven®RT) for the treatment of bleeding in non-hemophiliac cardiac surgery patients.
Wednesday, December 6, 2023
8:30 AM - 9:30 AM
Location: Hall E, Lower Level
Co-Author(s): Kelsi Crean, Les Louden, Tu Phan, Catherine Storms
